We've observed a clear trend in China's Cell and Gene Therapy (CGT) market in recent years. but there remains challenges around the prioritization of commercialization and research. In today’s market, innovative therapies have to go international. It is a high-risk high-cost business to ensure returns and worthwhileness. To achieve these goals, early planning is key for emerging cell and gene therapy developers.

From day one, companies should consider how their manufacturing, patient recruitment, and target markets will eventually synergize with their product’s commercialization.